# Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

> **NCT01068717** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 27 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)
- **DRUG:** Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)
- **DRUG:** Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
- **DRUG:** Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)

## Key facts

- **NCT ID:** NCT01068717
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068717, "Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01068717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*